1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  
March 2018  
April 2018  
May 2018  
June 2018  
July 2018  
August 2018  
September 2018  
October 2018  
November 2018  

This page is powered by Blogger. Isn't yours?

Wednesday, October 26, 2016

 

Study identifies 2 new genes responsible for Alzheimer's disease among African-Americans






Image Source: USATODAY

Researchers have identified two new genetic risk factors for Alzheimer's disease (AD) among African Americans.


The findings, which appear online in the journal Alzheimer's and Dementia, may lead to the development of new therapies specifically targeting those genes.

Despite the fact that AD is more common in African Americans than Caucasians, the AD genetic risk profile for African Americans is more poorly understood. While more than 20 genes have been identified as risk factors for AD in Caucasians, fewer than five have been identified for African Americans.

In 2013, a genome-wide association study of AD in more than 5,500 African Americans identified two genetic risk factors for AD. This study looked at genetic variants across subjects' entire genome and compared their frequency in cases versus controls. Researchers from Boston University School of Medicine (BUSM) used these same subjects, but added additional AD risk information (smoking status, diabetes status, education level) to their statistical modeling to increase the power of the study. By doing so they were able to identify two new genes (COBL and SLC10A2) associated with risk of AD in African Americans.

"There are currently no medications for AD that slow or stop the progression of the disease. Genes that increase  for AD are potential targets for new disease-modifying AD drug therapies. Our study identifies two potentially "" targets," explains corresponding author Jesse Mez, MD, MS, assistant professor of neurology at BUSM and associate director of the Boston University Alzheimer's Disease & CTE Center Clinical Core.

According to the  the methodology they employed for this study allowed them to make an important discovery without investing more money in genotyping or more effort to recruit volunteers. They believe  similar methodology could be used for many other diseases to make new genetic discoveries without new large investments.

"Despite the fact that Alzheimer's disease is more common in African Americans than Caucasians, we understand less about the genes that influence  of Alzheimer's in African Americans. Our hope is that this study begins to eliminate that disparity and that ultimately these newly identified genes become targets for Alzheimer's disease drug development," added Mez.

Story Source: The above story is based on materials provided by EUREKALERT
Note: Materials may be edited for content and length
Click here to read original article